Stockreport

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update [Yahoo! Finance]

Lumos Pharma, Inc.  (LUMO) 
PDF Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All Primary and Secondary Endpoints Pisit “Duke” P [Read more]